CROI 2015 Program and Abstracts

Keyword Index

• Infection; 324 • Microbicides; 269 • Squamous cell carcinoma; 717 • Tissue; 964 Recurrence; 830 Regression discontinuity; 1110 RegulatoryT cells; 284, 325, 326, 353, 819, 900 Relapse; 681 Remission; 373 Renal; 511 • Function; 793, 934 • Impairment; 795 • Insufficiency; 781, 781 • Tubular disease; 143LB, 794 Repeat testing; 1022 Repertoire; 355 Replicating effectiveness programs; 7 Replication; 394 Replication-competent reservoir; 414 Reproductive; 896 Reproductive hormone; 862 Reservoir; 21, 110LB, 374, 394, 423, 425 Residual viremia; 105, 168, 379, 389LB Resistance; 537, 596, 603, 696, 699 • Associated variants; 698 • Biopsy; 794 • Failure; 642

• Seq; 11, 258 • Splicing; 104LB Romidepsin; 406 Rosuvastatin; 733, 771 Routinely collected clinical markers; 619 RT-PCR; 420 RT/HBsAg variability; 702 Rural; 558 Rural Uganda; 458 RV144; 170LB

Shock and kill; 387 Short cycle therapy; 38LB shRNA screen; 46LB Side effects; 888 Sieve analysis; 55LB, 349 Siglec-1 (CD169); 283 Simeprevir; 149, 644, 645, 647, 648, 652 Simian foamy virus; 237 Simplification; 553 Single • Cell; 11 • Cell analysis; 421LB

Rwanda; 157, 780, 865, 1109 Rwanda Military Hospital; 700 – S – Safer conception; 895 Safety; 940, 954 SAHA; 407, 408, 409 SAMHD1; 203, 202, 202, 203, 205, 206, 207 Sample-to-cutoff ratio; 627 Sanctuary sites; 534 Saporin; 362 Saturation mutagenesis; 216 Scale-up; 175, 176, 1114 sCD14; 47, 268, 547, 778, 899 sCD163; 303, 316, 319, 676, 784, 806, 1050 School enrollment; 1036 Sclerostin; 767 Screen; 40 Screening; 90, 455, 658, 668, 710, 712, 727, 823 Second line; 457, 563 Second-line antiretroviral treatment; 782, 571, 782, 956 Second-line regimens; 552, 779 Second-line therapy; 119 Selection bias; 1102 Selenium; 567 Self-report; 555, 977 Self-reported condom use; 1030 Self-selection; 1088Self-testing; 634, 1103 Semen; 208, 209, 366 Semenogelin; 209 Senescence; 300 Sensitive testing; 982 Sequencing; 699 Sequential envs; 344 Serious adverse events; 648, 648 Seroconverters; 97, 602, 986

• Nucleotide polymorphism; 516 • Genome sequencing; 106, 396 • Round virus; 424 • Variant sequencing; 686 siRNA; 205 SIV; 108, 192, 203, 268, 286, 298LB, 324, 349, 361, 363, 370, 406, 416, 476, 503, 591, 948, 965, 966LB SIV/HIV chimeric viruses; 280 Skin; 941 Skin and soft tissue infections; 847 SLC22A1; 519 Sleep quality; 937 Smoking; 726, 727, 728, 743, 763, 901 Smoking cessation; 139 SNP; 682 Social; 74 Social media; 1098 Socioeconomic status; 560, 1036 Sofosbuvir; 148, 149, 151LB, 152LB, 644, 645, 646, 647, 648, 650, 652, 689, 692 Sofosbuvir phosphates; 81 Soluble CD163; 316, 744, 753 Soluble CD40 ligand; 284 South Africa; 26LB, 89, 92, 93, 724, 1110, 603, 724, 852, 921, 1033, 1080, 1091, 1110 Southern Africa; 718, 938 SPARTAC; 111LB

• Haplotypes; 593 • Mutations; 590 • Testing; 119 • Mutants; 589 • Mutation; 540

Resource Limited Settings; 156, 451, 459, 557, 571, 574, 604, 619, 779, 832, 920, 932, 1011, 1013, 1015, 1073, 1120 Respiratory isolation; 824 RestingT cells; 426 Restriction factor; 122, 190, 203, 204 Retention; 577, 584, 875, 1072 Retention in care; 100, 854, 890, 996, 1004, 1012, 1068, 1073, 1075, 1092 Retrovirus; 45 Return to care; 1002 Rev; 104LB, 201 Revaccination; 946 Reverse transcriptase; 255, 585 Reverse transcription; 200 Rhesus macaque; 50, 406, 965 Ribavirin; 691 Ribavirin triphosphate; 518 Rifabutin; 940 Rifampicin; 532 Rifampin; 521 Rifapentine; 827LB Rilpivirine; 554LB, 605, 737, 894 Risk; 1014 • Behavior; 850, 1018, 1021, 1022, 1024, 1058

Spatial analysis; 991LB Spatial mapping; 1045 Spirometry; 800 Spix’s owl monkey; 223 SQ109; 95LB Staphylococcus aureus; 846, 847 STAT5; 183 Statins; 136, 137, 502, 643, 734, 771 Statistical interaction; 562 Statistical power; 9 Stavudine; 781 Stem-cell transplantation; 430 Stigma; 1057, 1058, 1059 Stillbirth; 878 Strategies; 1079 Stribild; 113LB Stroke; 760

Serodiscordance; 314, 895, 1122 Serodiscordant couples; 969, 1035

Seroprevalence; 98, 667 Serosorting; 1062, 1063 Serum cholesterol; 781 Services; 1067 Set-point viral load; 1048

Severe immunodeficiency; 913 Severe non-AIDS events; 271, 562 Sex; 558 Sex workers; 853, 1031 Sexual

Structure; 412 Study design; 9 Subepidemic; 247

• Compensation; 1088 • Factor analysis; 674

Keyword Index

• Behavior; 1060, 1060 • Event coverage; 978LB • Positioning; 1063, 1063

• Factors; 297, 469, 713, 843, 1024 • Prediction; 88, 747, 751, 1017 • Score; 1017 Risky sexual behavior; 1039 RITA; 1042 Ritonavir-boosted lopinavir; 930, 956 Ritonavir-boosted protease inhibitor; 793 RNA; 42, 618 • Packaging; 45

Sub-Saharan Africa; 32, 781, 73, 115LB, 118, 153, 161, 570, 583, 624, 634, 711, 719, 721, 762, 781, 807, 874, 1071, 1073, 1075, 1090, 1101 Subgroups; 550 Substance use disorders; 804 Subtype; 201, 596, 622

• Risk behavior; 972, 1036, 1061 • Transmission; 214, 674, 1029 Sexually transmitted disease; 1047 Sexually transmitted infection (STI); 304, 568, 944, 962, 963, 1032, 1033, 1099 Shedding; 855 SHIV; 50, 344, 433

Subtype B; 229 Subtypes; 633 Sulfamethoxazole; 512

690

CROI 2015